1. Scrip
  2. >>Business
  3. >>Deals

Genmab Relies On Pipeline As J&J Opts Out Of Next-Gen Darzalex

Epkinly, Rina-S, Acasunlimab To Deliver Revenue Growth

 
• By Mandy Jackson

J&J’s decision about whether to in-license HexaBody-CD38 (GEN3014) was seen as a key milestone for Genmab this year, but without the opt-in the company is discontinuing development.

With or without a GEN3014 deal, Genmab is seeking growth through late-stage dealmaking (Shutterstock)
Key Takeaways
  • J&J will not in-license a next-generation anti-CD38 antibody asset, a decision closely watched by Genmab investors this year, and the company will not develop GEN3014 further on its own.
  • GEN3014 (HexaBody-CD38) could have extended the Darzalex franchise that provides most of Genmab’s royalties and overall revenue, but the company believes its late-stage pipeline will fill the void by 2030 when daratumumab royalties dry up.
  • Phase III readouts are expected starting in 2026 for Epkinly, Rina-S and acasunlimab.

The pressure on Genmab to deliver positive results from its late-stage development programs has intensified now that the most closely watched event on the company’s 2025 calendar has arrived and...

J&J was due to make a decision about in-licensing GEN3014 within 60 days of receiving Phase I/II data for the candidate in early January. Those data included head-to-head results against...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

Sanofi Makes Alzheimer’s Bet With Vigil Buy

 
• By Kevin Grogan

The French drugmaker is expanding its neurology activities with the $470m deal.

Genentech, Orionis Stick Together In Second Molecular Glue Deal

 
• By Alaric DeArment

Deal Snapshot: Orionis and Genentech signed a new partnership focused on molecular glues, on top of the one that they struck in 2023.

Pfizer Scoops 3SBio’s PD-1/VEGF Bispecific In ADC Combo Push

 
• By Dexter Jie Yan

Pfizer is doubling down on partnerships for combination therapies involving its antibody-drug conjugates through a new alliance with China's 3SBio’s for a bispecific antibody, potentially worth up to $6bn.

CRISPR Thinks Outside Gene-Editing Box With Sirius Deal

 
• By Alaric DeArment

The gene-editing company is making a deal with RNA interference-focused Sirius, but still focusing on cardiovascular disease, a major area of its pipeline.

More from Scrip

Genentech, Orionis Stick Together In Second Molecular Glue Deal

 
• By Alaric DeArment

Deal Snapshot: Orionis and Genentech signed a new partnership focused on molecular glues, on top of the one that they struck in 2023.

Finance Watch: Prime, Kyverna, Allogene And More Announce Job Cuts

 
• By Mandy Jackson

Restructuring Edition: Prime Medicine ended its sole clinical-stage program to prioritize preclinical and partnered programs, cutting 25% of its workforce to extend its cash runway. Meanwhile, earnings season brought workforce reductions at Kyverna, Allogene, Leap and others.

Merck KGaA Plans Phase III For Enpatoran After Mixed Phase II Lupus Data

 
• By Jessica Merrill

The Phase II study testing the novel TLR7/8 inhibitor met the primary endpoint in a cohort of patients with cutaneous lupus erythematosus and systemic lupus erythematosus with rash, but did not in patients with SLE.